Ligand Pharmaceuticals announced that the U.S. FDA has approved ZELSUVMI for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. The FDA approved ZELSUVMI as the first novel drug for the treatment of molluscum infections. ZELSUVMI is expected to be commercially available during the second half of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LGND:
- Ligand sees FY28 adjusted EPS $10.00-$10.50
- Ligand sees FY24 adjusted EPS $4.25-$4.75, consensus $4.17
- Sermonix Pharmaceuticals shares PK, baseline data tied to Lasofoxifene trials
- Ligand, Palvella expand partnership to accelerate QTORIN rapamycin development
- Sermonix announces five abstracts at 2023 SABCS